Kevin Sharp, Samsung Biologics head of global sales

Up­dat­ed: Sam­sung Bio leans in­to ADC, gene ther­a­py is an ‘area of in­ter­est’

South Ko­rea-head­quar­tered Sam­sung Bio is heav­i­ly ex­pand­ing its an­ti­body-drug con­ju­gate ca­pa­bil­i­ties and that gene ther­a­py is an “area of in­ter­est,” head of glob­al sales Kevin Sharp told End­points News. But Sharp was quick to note that the man­u­fac­tur­er does not want to “over­sat­u­rate” its of­fer­ings and would “be care­ful” where it in­vests.

In a move to bol­ster its ADC of­fer­ings, a new stand-alone fa­cil­i­ty is set to go live in Oc­to­ber this year and be op­er­a­tional in April 2025. Con­struc­tion for the fa­cil­i­ty in Song­do, about a half an hour dri­ve from Seoul, start­ed in March last year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.